Get notified when CRDF files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The auditor's report includes a going concern explanatory paragraph, indicating substantial doubt about the company's ability to continue operations.
Cardiff Oncology prices $9.8M primary offering at $1.05/share with warrants; insiders pay $1.455
Filed July 16, 2026 · ~1 min read
Key Changes
-
high
Cardiff Oncology is offering 9,293,078 shares with warrants at $1.05 per share ($1.455 for insiders), raising gross proceeds of about $9.76 million.
The Offering verify on EDGAR → -
high
The company expects net proceeds of approximately $9.1 million after fees and expenses, to be used for general corporate and working capital purposes.
Use of Proceeds verify on EDGAR → -
high
New investors pay an effective $1.08 per share while as-adjusted net tangible book value is $0.56, causing immediate dilution of $0.52 per share.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (WS 10-Q) is open in full — no account needed.
Partner
Trade CRDF commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify